Since only 40–50% of patients achieve a good and sustained reaction to anti-TNF treatment (Bálint et al. 2016), and the cause of the failure was primary non-response in most of our cases, validation of these finding would provide us with tools for a more personalized choice from the growing number of classes of targeted therapies in IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.